Early Phase Clinical Trial Program
The Early Phase Clinical Trial Infusion Center at Smilow Cancer Hospital opened in 2016 at 55 Park Street in New Haven, and is a dynamic hub of early phase trials. Attractive and state-of-the-art, the Center is at the heart of Yale Cancer Center’s Early Phase Clinical Trial Program and is dedicated to the care and treatment of patients on early phase clinical trials.
Under the leadership of Patricia LoRusso, DO Associate Director, Experimental Therapeutics, Yale Cancer Center, and Director of the Early Phase Clinical Trial Infusion Center, the Early Phase Clinical Trial Program affords patients hope, as well as the ability to participate in research with clinical impact – research that will advance new drugs, potentially leading to FDA approval.
The Early Phase Clinical Trial Program at Yale Cancer Center has a portfolio of early phase trials open to accrual; with the number of studies continually increasing. Among the most exciting of trials being conducted are first in-human, with some trials focusing on novel targets and other unique mechanisms in advanced solid tumors, which would have significant advancement for targeted therapeutics. Trials such as these have grown and developed Yale Cancer Center’s reputation for innovation in the immune-based therapy space.
For any sponsor/CRO inquiries regarding the Early Phase Clinical Trial Program, please send an email to: YCCPhase1CT@yale.edu. Emails are typically reviewed and responded to within 24-48 business hours by Natalie Walker, MSW (Program & Strategic Alliance Manager, Early Phase Clinical Trial Program) and Patricia LoRusso, DO (Associate Director, Experimental Therapeutics, Yale Cancer Center and Director of the Early Phase Clinical Trial Program).
For more information on the Early Phase Clinical Trial Program, please call